company background image
PAHC

Phibro Animal Health NasdaqGM:PAHC Stock Report

Last Price

US$18.70

Market Cap

US$757.4m

7D

-4.4%

1Y

-22.0%

Updated

06 Aug, 2022

Data

Company Financials +
PAHC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance4/6
Financial Health4/6
Dividends2/6

PAHC Stock Overview

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States.

Phibro Animal Health Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Phibro Animal Health
Historical stock prices
Current Share PriceUS$18.70
52 Week HighUS$26.55
52 Week LowUS$17.28
Beta0.51
1 Month Change-4.93%
3 Month Change-0.16%
1 Year Change-22.02%
3 Year Change-39.29%
5 Year Change-52.84%
Change since IPO10.00%

Recent News & Updates

Jul 29
Phibro Animal Health (NASDAQ:PAHC) Has Affirmed Its Dividend Of $0.12

Phibro Animal Health (NASDAQ:PAHC) Has Affirmed Its Dividend Of $0.12

Phibro Animal Health Corporation's ( NASDAQ:PAHC ) investors are due to receive a payment of $0.12 per share on 28th of...

Jul 25

Phibro Animal declares $0.12 dividend

Phibro Animal (NASDAQ:PAHC) declares $0.12/share quarterly dividend, in line with previous. Forward yield 2.56% Payable Sept. 28; for shareholders of record Sept. 7; ex-div Sept. 6. See PAHC Dividend Scorecard, Yield Chart, & Dividend Growth.

May 06
Phibro Animal Health's (NASDAQ:PAHC) Dividend Will Be US$0.12

Phibro Animal Health's (NASDAQ:PAHC) Dividend Will Be US$0.12

Phibro Animal Health Corporation's ( NASDAQ:PAHC ) investors are due to receive a payment of US$0.12 per share on 22nd...

Shareholder Returns

PAHCUS PharmaceuticalsUS Market
7D-4.4%-3.0%1.0%
1Y-22.0%1.8%-12.8%

Return vs Industry: PAHC underperformed the US Pharmaceuticals industry which returned 1.8% over the past year.

Return vs Market: PAHC underperformed the US Market which returned -12.8% over the past year.

Price Volatility

Is PAHC's price volatile compared to industry and market?
PAHC volatility
PAHC Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement12.0%
Market Average Movement8.1%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market3.2%

Stable Share Price: PAHC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: PAHC's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19461,725Jack Bendheimhttps://www.pahc.com

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.

Phibro Animal Health Fundamentals Summary

How do Phibro Animal Health's earnings and revenue compare to its market cap?
PAHC fundamental statistics
Market CapUS$757.42m
Earnings (TTM)US$58.81m
Revenue (TTM)US$907.27m

12.9x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PAHC income statement (TTM)
RevenueUS$907.27m
Cost of RevenueUS$630.39m
Gross ProfitUS$276.88m
Other ExpensesUS$218.07m
EarningsUS$58.81m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 24, 2022

Earnings per share (EPS)1.45
Gross Margin30.52%
Net Profit Margin6.48%
Debt/Equity Ratio155.8%

How did PAHC perform over the long term?

See historical performance and comparison

Dividends

2.6%

Current Dividend Yield

33%

Payout Ratio

Does PAHC pay a reliable dividends?

See PAHC dividend history and benchmarks
When do you need to buy PAHC by to receive an upcoming dividend?
Phibro Animal Health dividend dates
Ex Dividend DateSep 06 2022
Dividend Pay DateSep 28 2022
Days until Ex dividend30 days
Days until Dividend pay date52 days

Does PAHC pay a reliable dividends?

See PAHC dividend history and benchmarks
We’ve recently updated our valuation analysis.

Valuation

Is PAHC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PAHC?

Other financial metrics that can be useful for relative valuation.

PAHC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA10.5x
PEG Ratio-1.1x

Price to Earnings Ratio vs Peers

How does PAHC's PE Ratio compare to its peers?

PAHC PE Ratio vs Peers
The above table shows the PE ratio for PAHC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average46.6x
AVIR Atea Pharmaceuticals
15.1x45.3%US$731.8m
COLL Collegium Pharmaceutical
n/a41.2%US$685.9m
INVA Innoviva
10.1xn/aUS$1.0b
AMYT Amryt Pharma
180.7x73.5%US$505.1m
PAHC Phibro Animal Health
12.9x-11.3%US$757.4m

Price-To-Earnings vs Peers: PAHC is good value based on its Price-To-Earnings Ratio (12.9x) compared to the peer average (46.6x).


Price to Earnings Ratio vs Industry

How does PAHC's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Earnings vs Industry: PAHC is good value based on its Price-To-Earnings Ratio (12.9x) compared to the US Pharmaceuticals industry average (19.3x)


Price to Earnings Ratio vs Fair Ratio

What is PAHC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PAHC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.9x
Fair PE Ratio13.9x

Price-To-Earnings vs Fair Ratio: PAHC is good value based on its Price-To-Earnings Ratio (12.9x) compared to the estimated Fair Price-To-Earnings Ratio (13.9x).


Share Price vs Fair Value

What is the Fair Price of PAHC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PAHC ($18.7) is trading above our estimate of fair value ($14.15)

Significantly Below Fair Value: PAHC is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Future Growth

How is Phibro Animal Health forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-11.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PAHC's earnings are forecast to decline over the next 3 years (-11.3% per year).

Earnings vs Market: PAHC's earnings are forecast to decline over the next 3 years (-11.3% per year).

High Growth Earnings: PAHC's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PAHC's revenue (4.1% per year) is forecast to grow slower than the US market (7.9% per year).

High Growth Revenue: PAHC's revenue (4.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PAHC's Return on Equity is forecast to be low in 3 years time (18.8%).


Discover growth companies

Past Performance

How has Phibro Animal Health performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-8.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PAHC has high quality earnings.

Growing Profit Margin: PAHC's current net profit margins (6.5%) are higher than last year (5.4%).


Past Earnings Growth Analysis

Earnings Trend: PAHC's earnings have declined by 8.1% per year over the past 5 years.

Accelerating Growth: PAHC's earnings growth over the past year (37.1%) exceeds its 5-year average (-8.1% per year).

Earnings vs Industry: PAHC earnings growth over the past year (37.1%) exceeded the Pharmaceuticals industry 15.5%.


Return on Equity

High ROE: Whilst PAHC's Return on Equity (22.03%) is high, this metric is skewed due to their high level of debt.


Discover strong past performing companies

Financial Health

How is Phibro Animal Health's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PAHC's short term assets ($546.5M) exceed its short term liabilities ($187.1M).

Long Term Liabilities: PAHC's short term assets ($546.5M) exceed its long term liabilities ($462.1M).


Debt to Equity History and Analysis

Debt Level: PAHC's net debt to equity ratio (119.8%) is considered high.

Reducing Debt: PAHC's debt to equity ratio has reduced from 221.8% to 155.8% over the past 5 years.

Debt Coverage: PAHC's debt is not well covered by operating cash flow (8%).

Interest Coverage: PAHC's interest payments on its debt are well covered by EBIT (6x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Phibro Animal Health current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


2.57%

Current Dividend Yield

Upcoming Dividend Payment

TodayAug 07 2022Ex Dividend DateSep 06 2022Dividend Pay DateSep 28 202222 days from Ex DividendBuy in the next 30 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: PAHC's dividend (2.57%) is higher than the bottom 25% of dividend payers in the US market (1.52%).

High Dividend: PAHC's dividend (2.57%) is low compared to the top 25% of dividend payers in the US market (4.09%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, PAHC has been paying a dividend for less than 10 years.

Growing Dividend: PAHC's dividend payments have increased, but the company has only paid a dividend for 8 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (33.1%), PAHC's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (2167.4%), PAHC's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average management tenure


CEO

Jack Bendheim (75 yo)

34.58yrs

Tenure

US$4,001,319

Compensation

Mr. Jack Clifford Bendheim has been the President and Chief Executive Officer of Phibro Animal Health Corporation since 1988 and March 2014, respectively and serves as its Chairman. Mr. Bendheim served as...


CEO Compensation Analysis

Compensation vs Market: Jack's total compensation ($USD4.00M) is about average for companies of similar size in the US market ($USD3.94M).

Compensation vs Earnings: Jack's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: PAHC's management team is seasoned and experienced (5.4 years average tenure).


Board Members

Experienced Board: PAHC's board of directors are seasoned and experienced ( 14.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Phibro Animal Health Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Phibro Animal Health Corporation
  • Ticker: PAHC
  • Exchange: NasdaqGM
  • Founded: 1946
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$757.417m
  • Shares outstanding: 40.50m
  • Website: https://www.pahc.com

Number of Employees


Location

  • Phibro Animal Health Corporation
  • Glenpointe Centre East
  • 3rd Floor
  • Teaneck
  • New Jersey
  • 07666-6712
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/06 00:00
End of Day Share Price2022/08/05 00:00
Earnings2022/03/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.